Amarantus Bioscience Holdings, Inc. (OTCBB:AMBS) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Amarantus Bioscience Holdings (OTCBB AMBS) traded up 52.778% during midday trading on Friday, reaching $0.055. The company’s stock had a trading volume of 736,893 shares. Amarantus Bioscience Holdings has a 52-week low of $0.01 and a 52-week high of $0.09. The stock’s market capitalization is $3.75 million. The firm has a 50-day moving average price of $0.03 and a 200 day moving average price of $0.04.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/09/amarantus-bioscience-holdings-inc-ambs-rating-increased-to-sell-at-valuengine.html.

Amarantus Bioscience Holdings Company Profile

Amarantus BioScience Holdings, Inc, a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis.

Receive News & Stock Ratings for Amarantus Bioscience Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarantus Bioscience Holdings Inc. and related stocks with our FREE daily email newsletter.